Clinical and functional outcomes after curative resection in octogenarians with clinical stage I non-small cell lung cancer

Laohathai, Sira; Cho, Sukki; Yum, Sungwon; Jang, Hyung Suk; Seong, Yong Won; Kim, Kwhanmien; Jheon, Sanghoon

doi:10.1016/j.jgo.2018.08.011

Cited by 6 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lung cancer represents one of the most commonly diagnosed cancer with rapid progress, high metastatic, and high mortality [1][2][3]. Despite the development of a wide range of novel therapeutic methods, the treatment e cacy of lung cancer remain dissatisfactory with and overall 5-year survival rate was only 10% around [2,4]. It have been demonstrated that a wide array of proteins were involved in the tumorigenesis, progress, metastasis, and drug-resistance of lung cancer [17][18][19].…”

Section: Discussionmentioning

confidence: 99%

“…According to the statistics, the morbidity and mortality of lung cancer ranks rst among men [3]. The non-small cell lung cancer (NSCLC) represents one of the most aggressive type of lung cancer, which accounts for 85% all mortality cases globally [4,5]. Treatment of NSCLC are still seriously blocked by the rapid metastasis, fast progress, and insu cient therapy approaches [6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

WITHDRAWN: PYCR1 Promotes Proliferation, Invasion and Drug-Resistance of Lung Cancer Cells by Regulating STAT3-Mediated PI3K/AKT and NF-κB Signaling Pathway

Yu¹,

Wang²,

Zhang³

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background: Aberrant expression of PYCR1 has been proved to be one of the most pivotal regulators of tumor progress and metastasis. However, the detailed role of PYCR1 in promotion of NSCLC progress is not investigated thoroughly. The present study was aimed to thoroughly investigate the effect of PYCR1 in the growth of NSCLC and the underlying mechanisms, so that provide valuable theoretical basis for efficient treatment of NSCLC. Methods: The expressions of PYCR1 and its target genes and downstream signals were respectively determined by Western-blot assay and RT-qPCR experiment. Cell growth of NSCLC cells was investigated using the CCK-8 kit while the proliferation assay was performed with the help of EDU staining. The NSCLC-bearing mice mode was established to evaluate the effect of PYCR1 on the progress of NSCLC and the underlying mechanisms in vivo.Results: It was firstly demonstrated that the PYCR1 was overexpressed in lung cancer tissues and cells and overexpression of PYCR1 contributed to significantly enhanced proliferation, invasion, and drug-resistance of cancer cells and progress of NSCLC tissues. Further studies revealed that up-regulation of PYCR1 level resulted to the elevation of bioactivity of STAT3. Additionally, the positive correlation between the expression of PYCR1 and STAT3 indicated that the PYCR1 promotes the growth of NSCLC through targeting regulation the STAT3 levels. Furthermore, activation of STAT3 by PYCR1 was proved to be able of awaking the PI3K/AKT and NF-κB signaling pathway, which was extremely important to the metabolism, proliferation, cell survival, and growth of many cancer cell types.Conclusion: In conclusion, our study demonstrated that PYCR1 was specifically overexpressed in lung cancer and closely related to rapid progress and drug-resistance thorough regulating the STAT3-mediated PI3K/AKT and NF-κB signaling pathway. It may provide a valuable strategy for treatment of malignant lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

WITHDRAWN: PYCR1 Promotes Proliferation, Invasion and Drug-Resistance of Lung Cancer Cells by Regulating STAT3-Mediated PI3K/AKT and NF-κB Signaling Pathway

Yu¹,

Wang²,

Zhang³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…A better 30-day OM for sublobar resection is expected given that limited resection has been shown to have less postoperative morbidity and mortality compared with a lobectomy. 5,11,12 This suggests that in elderly patients with increased comorbidities and poor lung reserves, sublobar resection may still be justified over a lobectomy to reduce perioperative morbidity, which is a known predictor for worse outcomes. [13][14][15]31 Our meta-analysis has several limitations.…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…With a shorter life expectancy, elderly patients may benefit by having a lung sparing sublobar resection for stage 1 NSCLC, given that sublobar resection preserves lung function and decreases morbidity that improves their postoperative recovery. 5,11,12 Furthermore, it has been shown that perioperative morbidity is a strong predictor for overall survival (OS) in the frail elderly. [13][14][15] Little focus has been placed on comparing lobectomy and sublobar resection specifically in the elderly population, a target group that could stand to benefit immensely from less radical surgery.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Lobar versus Sublobar Resection in the Elderly for Early Lung Cancer: A Meta-Analysis

Leow

et al. 2021

Thorac Cardiovasc Surg

View full text Add to dashboard Cite

Objectives We performed a systematic review and meta-analysis of outcomes of lobectomy versus sublobar resection in elderly patients (≥65) with stage 1 nonsmall cell lung carcinoma (NSCLC). Methods We searched for relevant articles using a set of inclusion and exclusion criteria. Meta-analytic techniques were applied. Results Twelve studies (n = 5834) were chosen. Our results indicate that in the elderly, lobectomy for stage 1 NSCLC confers a survival advantage over sublobar resection. Lobectomy patients had a lower risk of death within 5 years and lower odds of local cancer recurrence. Our results show that lobectomy had a better 5-year cancer-specific survival and 5-year disease-free survival that trended toward significance. The sublobar resection group showed better 30-day operative mortality that trended toward significance. Subgroup analysis of stage 1A cancer demonstrated no difference in 5-year overall survival rates. However, for stage 1B tumors 5-year overall survival favored lobectomy. Conclusion Lobectomy for stage 1 NSCLC in elderly patients is superior to sublobar resection in terms of survival and cancer recurrence and should be afforded where possible. For stage 1A tumors, sublobar resection is noninferior and may be considered. Further randomized controlled trials in this topic is required.

show abstract

Safety of curative-intent lung cancer surgery in older patients (octogenarians): A contemporary multicentre cohort study

King,

Taylor,

Booton

et al. 2023

Journal of Geriatric Oncology

View full text Add to dashboard Cite

Clinical and functional outcomes after curative resection in octogenarians with clinical stage I non-small cell lung cancer

Cited by 6 publications

References 8 publications

WITHDRAWN: PYCR1 Promotes Proliferation, Invasion and Drug-Resistance of Lung Cancer Cells by Regulating STAT3-Mediated PI3K/AKT and NF-κB Signaling Pathway

WITHDRAWN: PYCR1 Promotes Proliferation, Invasion and Drug-Resistance of Lung Cancer Cells by Regulating STAT3-Mediated PI3K/AKT and NF-κB Signaling Pathway

Lobar versus Sublobar Resection in the Elderly for Early Lung Cancer: A Meta-Analysis

Safety of curative-intent lung cancer surgery in older patients (octogenarians): A contemporary multicentre cohort study

Contact Info

Product

Resources

About